SCHEDULE: Deep Track Capital Reduces Viridian Therapeutics Stake

Deep Track Capital and affiliates have reduced their beneficial ownership in Viridian Therapeutics to 2.65%, falling below the 5% threshold.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an Amendment No. 3 to their Schedule 13G.
• The reporting persons collectively beneficially own 2,524,833 shares of Viridian Therapeutics, Inc. common stock.
• This ownership represents 2.65% of the issuer's common stock, based on 95,442,008 shares outstanding as of October 31, 2025.
• The filing indicates a reduction in their stake to below the 5% threshold, as this is an amendment to a previous filing that would have required reporting a stake above 5%.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal, as a reduction in a significant institutional stake often suggests a less favorable outlook from a key investor, though it is not a complete exit.

Negatives

• The beneficial ownership percentage of Deep Track Capital and its affiliates in Viridian Therapeutics, Inc. has decreased to 2.65%, falling below the 5% threshold, which typically signals a reduction in investment by a significant institutional holder.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a reduction in a significant institutional investor's stake, particularly below the 5% reporting threshold, can be interpreted by the market as a diminished conviction in the company's near-term prospects or a reallocation of capital to other opportunities within the biotechnology sector.

Stakeholder Impact

• Shareholders may perceive this reduction in institutional ownership as a negative signal, potentially leading to downward pressure on the stock price.
• The company's management might face questions regarding the reasons for the institutional investor's reduced stake.

Key Dates

Recommendation

A seasoned investor would likely place a 'hold' recommendation with a cautious outlook. While the reduction in Deep Track Capital's stake below the 5% threshold is a negative signal, it is not a complete divestment. Investors should monitor future filings and company performance closely, as this could indicate a shift in institutional sentiment or portfolio rebalancing rather than a fundamental deterioration of the company's prospects. Further analysis of Viridian Therapeutics' operational updates and financial results would be crucial before making a 'sell' decision.

Keywords

Viridian Therapeutics, Deep Track Capital, Beneficial Ownership, Schedule 13G, Institutional Investment, Common Stock, Biotechnology